Peel Hunt upgraded shares of Abcam (LON:ABC) to a buy rating in a research note issued to investors on Wednesday morning. Peel Hunt currently has GBX 1,330 ($17.38) target price on the stock, down from their previous target price of GBX 1,350 ($17.64).
Other equities research analysts have also issued research reports about the stock. Berenberg Bank restated a buy rating and issued a GBX 1,640 ($21.43) target price on shares of Abcam in a report on Tuesday. Numis Securities restated a hold rating on shares of Abcam in a report on Tuesday, September 11th. Finally, JPMorgan Chase & Co. restated a neutral rating on shares of Abcam in a report on Wednesday, January 2nd.
Abcam stock opened at GBX 1,216 ($15.89) on Wednesday. Abcam has a 12-month low of GBX 9.73 ($0.13) and a 12-month high of GBX 1,290 ($16.86).
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.
See Also: Stochastic Momentum Index (SMI)
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.